KEYNOTE-966 Long-Term Follow-Up Confirms Durable Survival Benefit and Manageable Safety of Pembrolizumab Chemoimmunotherapy
核心洞察
Long-term follow-up of KEYNOTE-966 shows the addition of pembrolizumab to gemcitabine and cisplatin maintained a clinically meaningful overall survival benefit with no new safety signals.
Overall grade 3 or 4 adverse event rates were comparable between treatment arms, with cytopenias as the most common events attributable to the chemotherapy backbone.
Immune-mediated adverse events and infusion reactions occurred more often with pembrolizumab, most commonly hypothyroidism and pneumonitis.
With long-term follow-up, the addition of pembrolizumab to gemcitabine and cisplatin maintained a clinically meaningful overall survival benefit with no new safety signals, according to a panel review of the KEYNOTE-966 data. The findings reinforce the role of chemoimmunotherapy in this setting while providing clinicians with a clearer picture of the treatment's long-term safety profile.
Long-Term Efficacy and Safety
The KEYNOTE-966 long-term follow-up data demonstrate that the overall survival benefit associated with adding pembrolizumab to the gemcitabine and cisplatin chemotherapy backbone was maintained over time. Importantly, no new safety signals emerged with extended follow-up, supporting the durability of both the efficacy and tolerability profile of this combination.
Regarding adverse events, overall grade 3 or 4 adverse event rates were comparable between treatment arms. The most common events were cytopenias, which were consistent with and attributable to the chemotherapy backbone rather than the immunotherapy component. This pattern underscores that the addition of pembrolizumab did not meaningfully compound the hematologic toxicity burden typically associated with gemcitabine and cisplatin.
Immune-Mediated Adverse Events
Immune-mediated adverse events and infusion reactions occurred more often with pembrolizumab than in the comparator arm. The most commonly observed immune-mediated adverse events were hypothyroidism and pneumonitis. These findings are consistent with the known safety profile of PD-1 inhibitors and highlight the importance of routine monitoring for endocrine and pulmonary immune-related toxicities in patients receiving this regimen.
Comparison with TOPAZ-1
The faculty discussed how the KEYNOTE-966 data relate to the TOPAZ-1 study and how they compare to current practice. In TOPAZ-1, grade 3 or 4 adverse events were similar between arms, and discontinuation due to adverse events was comparable. The most common events in TOPAZ-1 were also hematologic and attributable to the chemotherapy backbone. Immune-mediated adverse events occurred more often with durvalumab in TOPAZ-1 but were generally manageable.
Taken together, the KEYNOTE-966 and TOPAZ-1 datasets provide a consistent picture of chemoimmunotherapy safety in this disease setting, with manageable immune-mediated toxicities and a hematologic toxicity profile driven primarily by the chemotherapy backbone.
Practical Implications
The faculty concluded with practical counseling strategies, emphasizing the importance of informing patients about the expected cytopenias related to chemotherapy and the potential for immune-mediated adverse events such as hypothyroidism and pneumonitis. These counseling points aim to support early recognition and management of treatment-related toxicities while preserving the clinically meaningful overall survival benefit demonstrated with pembrolizumab-based chemoimmunotherapy.